• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » UAE, Merck Serono, Neopharma form first pharmaceutical production agreement

UAE, Merck Serono, Neopharma form first pharmaceutical production agreement

December 5, 2012
CenterWatch Staff

Merck Serono, a division of Germany-based Merck, and a local manufacturer, Neopharma, have formed the first partnership of its kind to locally produce Merck branded medication in the UAE for distribution across the Middle East.

Merck Serono will be the first multinational pharmaceutical company to work with a local manufacturer to cater to regional demand for key pharmaceutical products through export out of the UAE manufacturing base. Initially, two Merck Serono products will be manufactured by Neopharma: Euthyrox , a hormone therapy requiring a very stringent sterile environment for production and packaging, and Glucophage, a standard oral treatment for people suffering from type 2 diabetes that helps control blood sugar levels. Production of both branded medications will begin in 2013.

"Currently valued at approximately 1.4 billion and growing at 6.8% annually, the UAE pharmaceutical market is one of the most developed markets in the Middle East, with a strong healthcare infrastructure and the highest per-capita medicine expenditure in the region,” said Sheikh Nahyan bin Mubarak Al Nahyan, chairman of Neopharma and Minister of Higher Education and Scientific Research. "This partnership characterizes our country's rapidly developing healthcare industry and improved production capabilities, putting it on-par with international standards of pharmaceutical production."

Stefan Oschmann, CEO of Merck Serono, said, “After careful consideration of the production capabilities of various companies across the Middle East, we identified Neopharma as having the most advanced, European-standard manufacturing facilities capable of producing significant quantities of both hormone and regular pharmaceutical drug products.”

Traditionally the local manufacturing sector in the UAE has been relatively small and focuses on basic medicines. Until this alliance, the market relied on imports for pharmaceutical prescriptions. In 2010, nearly 64% of pharmaceutical imports came from Europe, around 8% from North America and another 8% from the MENA region.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing